All In MedTech

Device Trial Radar · NCT07081815

JOCOAT Safety and Tolerability Clinical Trial GLAD-04

A Single Center Clinical Trial Investigating the Safety and Efficacy of JOCOAT(TM) APN-3003 Liquid Adhesion Barrier Device for Knee Anterior Cruciate Ligament Reconstruction Surgery

Last checked: Nov 19, 2026Latest source record: Nov 18, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

24

Planned (sponsor's estimate)

Start

Sep 5, 2025

Primary completion

Nov 2026

Study completion Nov 2027

Sponsor

Lead sponsor
ARC Medical Inc.Not on our public-company list
Sponsor type
Industry
First posted
Jul 23, 2025

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Prevention
FDA-regulated device
No
Who can join
All sexes, from 15 years, up to 25 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study will assess the safety and efficacy of a new liquid anti-adhesion device, JOCOAT(TM) APN-3003 in patients undergoing knee anterior cruciate ligament reconstruction (ACLR) surgery. This is a single-center, prospective study. Safety and clinical outcomes will be compared with historical controls from enrolled study site patients from NCT03935750 (STABILITY 2) which has evaluated outcomes following ACL rupture in young athletes. A maximum of 24 patients aged 15-25 years undergoing primary anatomic ACLR with quadriceps tendon (QT) graft following a standardized surgical treatment algorithm will be enrolled. All patients will receive JOCOAT(TM) APN-3003 at the end of their surgery.

Conditions

  • Surgical Adhesions

Interventions

  • JOCOAT(TM) APN-3003Device

    10 mL of JOCOAT(TM) APN-3003 is applied at the end of surgery

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Safety of JOCOAT(TM) APN-3003 as measured by number and severity of adverse device effects and serious adverse device effectsTime frame: 3 months after surgery

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Western University

    London, Ontario, Canada · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.